Telbivudine improves the function of myeloid dendritic cells in patients with chronic hepatitis B

Acta Virologica

Volumn 56, Issue 1, 2012, Pages 31-38

  Pan, Xiucheng ^a   Yao, Wei ^a   Fu, Juanjuan ^a   Liu, Mei ^a   Li, Li ^a   Gao, Xiyang ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Dendritic cell; Telbivudine

Indexed keywords

ALPHA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; PROGRAMMED DEATH 1 LIGAND 1; TELBIVUDINE; ANTIVIRUS AGENT; CD274 PROTEIN, HUMAN; HEPATITIS B ANTIGEN; LEUKOCYTE ANTIGEN; NUCLEOSIDE; PYRIMIDINONE DERIVATIVE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HEPATITIS B; HUMAN; HUMAN CELL; MALE; MONOCYTE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; DENDRITIC CELL; DOWN REGULATION; GENE EXPRESSION; IMMUNOLOGY; PATHOLOGY; UPREGULATION; VIROLOGY; VIRUS REPLICATION;

ADULT; ANTIGENS, CD; ANTIGENS, CD274; ANTIVIRAL AGENTS; CELLS, CULTURED; DENDRITIC CELLS; DOWN-REGULATION; GENE EXPRESSION; HEPATITIS B ANTIGENS; HEPATITIS B, CHRONIC; HLA-DR ANTIGENS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-12; MALE; MONOCYTES; MYELOID CELLS; NUCLEOSIDES; PYRIMIDINONES; UP-REGULATION; VIRUS REPLICATION;

EID: 84862243752     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2012_01_31     Document Type: Article

References (27)

1. Akdis CA, Blaser K (2001): Mechanisms of interleukin-10-mediated immune suppression. Immunology 103, 131-136. http://dx.doi.org/10.1046/j.1365-2567.2001.01235.x
2. Chen LG, Zhang Z, Chen WW, Zhang Z, Li Y, Shi M, Zhang J, Chen L, Wang S, Wang FS (2007): B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J. Immunol. 178, 6634-6641.
3. Duan XZ, Zhuang H, Wang M, Li HW, Liu JC, Wang FS (2005): Decreased numbers and impaired function of circulating dendritic cell subsets in patients with chronic hepatitis B infection (R2). J.Gastroenterol. Hepatol. 20, 234-242. http://dx.doi.org/10.1111/j.1440-1746.2004.03529.x
4. Grandvaux N, Tenoever BR, Servant MJ, Hiscott J (2002): The IFN-antiviral response: from viral invasion to evasion. Curr. Opin. Infect. Dis. 15, 259-267. http://dx.doi. org/10.1097/00001432-200206000-00008
5. Lau GK (2010): Current treatments for patients with HBeAgpositive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver. Inter. 30, 512-519. http://dx.doi.org/10.1111/j.1478-3231.2009.02198.x
6. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ, Hoogsteden HC, Lambrecht BN. (2006): Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur. J. Immunol. 36, 2472-2482. http://dx.doi.org/10.1002/eji.200635978
7. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A (2002): Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver disease. J. Hepatol. 36, 734-741. http://dx.doi.org/10.1016/S0168-8278(02)00062-4
8. Langrish CL, McKenzie BS, Wilson NJ, Malefyt RW, Kastelein RA, Cua DJ (2004): IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202, 96-105. http://dx.doi.org/10.1111/j.0105-2896.2004.00214.x
9. Liu YJ (2001): Dendritic cell subsets and lineages, and their function in innate and adaptive immunity. Cell 106, 259-262. http://dx.doi.org/10.1016/S0092-8674(01)00456-1
10. Lu GF, Tang FA, Zheng PY, Yang PC, Qi YM (2008): Entecavir upregulates dendritic cell function in patients with chronic hepatitis B. World. J. Gastroenterol. 14, 1617-1621., http://dx.doi.org/10.3748/wjg.14.1617
11. Martin-Orozco N, Wang YH, Yagita H, Dong C (2006): Cutting edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8 T cell tolerance to tissue antigens. J. Immunol. 177, 8291-8295.
12. Matthews SJ (2007): Telbivudine for the management of chronic hepatitis B virus infection. Clin. Ther. 29, 2635-2653. http://dx.doi.org/10.1016/j.clinthera.2007.12.032
13. Nishimura H, Honjo T (2000): PD-1 an inhibitory immunoreceptor involved in peripheral tolerance. Trends. Immunol. 22, 265-268. http://dx.doi.org/10.1016/S1471-4906(01)01888-9
14. Opden Brouw ML, Binda RS, Roosmalen MH, Protzer U, Janssen HL, Van Der Molen R, Woltman AM. (2009): Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 126, 280-289. http://dx.doi. org/10.1111/j.1365-2567.2008.02896.x
15. Rehermann B, Nascimbeni M (2005): Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215-229. http://dx.doi.org/10.1038/nri1573
16. Reith WS, Landmann LG, Waldburger JM (2005): Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 5, 793-806. http://dx.doi.org/10.1038/nri1708
17. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ (1999): The nature of the principal type 1 IFN-producing cells in human blood. Science 284, 1835-1837. http://dx.doi.org/10.1126/science.284.5421.1835
18. Tavakoli S, Mederacke I, Herzog-HauffS, Glebe D, Grun S, Strand D, Urban S, Gehring A, Galle PR, Bocher WO (2008): Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin. Exp. Immunol. 151, 61-70. http://dx.doi. org/10.1111/j.1365-2249.2007.03547.x
19. Trinchieri G (2003): Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146. http://dx.doi.org/10.1038/nri1001
20. Ulsenheimer A, Gerlach JT, Jung MC, Gruener N, Wächtler M, Backmund M, Santantonio T, Schraut W, Heeg MH, Schirren CA, Zachoval R, Pape GR, Diepolder HM (2005): Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41, 643-651. http://dx.doi.org/10.1002/hep.20592
21. Untergasser A, Zedler U, Langenkamp A, Hosel M, Quasdorff M, Esser K, Dienes HP, Tappertzhofen B, Kolanus W, Protzer U (2006): Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539-547. http://dx.doi.org/10.1002/hep.21048
22. Vander Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. (2006): Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 44, 907-914. http://dx.doi. org/10.1002/hep.21340
23. Van der Molen RG, Sprengers D, Binda RS, Jong EC, Niesters HG, Kusters JG, Kwekkeboom J, Janssen HL. (2004): Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40, 38-746. http://dx.doi.org/10.1002/hep.20366
24. Wang K, Fan X, Fan Y, Wang B, Han L, Hou Y (2007): Study on the function of circulating plasmacytoid dendritic cells in the immunoactive phase of patients with chronic genotype B and C HBV infection. J. Viral. Hepat. 14, 276-282. http://dx.doi.org/10.1111/j.1365-2893.2006.00819.x
25. Zhang Z, Fu JL, Zhao QX, He Y, Jin L, Zhang H, Yao JX, Zhang LQ, Wang FS (2006): Differential restoration of myeloid and plasmacytoid dendritic cells in HIV-1-infected children aft er treatment with highly active antiretroviral therapy. J. Immunol. 176, 5644-5651.
26. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, Lee SS, Wen YM (2004): Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J. Viral. Hepat. 11, 217-224. http://dx.doi.org/10.1111/j.1365-2893.2004.00497.x
27. Zheng PY, Zhang DY, Lu GF, Yang PC, Qi YM, Wang BS (2007): Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection. World. J. Gastroenterol. 13, 4641-4645.